Your browser doesn't support javascript.
loading
Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.
Puig, L; Tsai, T-F; Bhutani, T; Uy, J; Ramachandran, P; Song, M; You, Y; Gooderham, M; Lebwohl, M.
Affiliation
  • Puig L; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Tsai TF; National Taiwan University Hospital, Taipei, Taiwan.
  • Bhutani T; University of California San Francisco Medical Center, San Francisco, CA, USA.
  • Uy J; Janssen Scientific Affairs, LLC, Horsham, PA, USA.
  • Ramachandran P; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Song M; Janssen Research & Development, LLC, Spring House, PA, USA.
  • You Y; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Gooderham M; SKiN Centre for Dermatology, Peterborough, ON, Canada.
  • Lebwohl M; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
J Eur Acad Dermatol Venereol ; 34(8): 1744-1749, 2020 Aug.
Article in En | MEDLINE | ID: mdl-32289190
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Psoriasis / Latent Tuberculosis Type of study: Clinical_trials Limits: Humans Language: En Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Psoriasis / Latent Tuberculosis Type of study: Clinical_trials Limits: Humans Language: En Year: 2020 Type: Article